LIDDS AB (publ)

LIDDS AB (publ), a pharmaceutical company headquartered in Uppsala, Sweden, specializes in the research, development, and marketing of therapeutic agents for cancer and various other medical conditions. The firm's innovative pipeline includes several drug candidates: NZ-2HOF is being advanced for prostate cancer; NZ-DTX targets a broad spectrum of malignancies such as breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX is in development for solid tumors; NZ-IO represents an immunotherapy; NZ-STING focuses on immuno-oncology; and NZ-TLR9 aims to bolster cancer immunotherapies. Additionally, LIDDS AB (publ) maintains a collaborative partnership with PharmIdea SIA, concentrating efforts on anti-cancer medications and the creation of sterile drug formulations.